论文部分内容阅读
40例糖化血红蛋白>9%的2型糖尿病患者随机分为胰岛素组和利拉鲁肽组(n=20),22例为对照,采用肺功能仪测定肺通气功能指标和DLCO(一氧化碳肺弥散功能)。结果与对照组相比,2型糖尿病患者的肺通气功能指标(VC、FVC、FEV1、TLC、MVV)和DLCO明显下降(P<0.05)。12周后胰岛素组肺通气功能指标轻度增加,但无统计学意义,而弥散功能指标DLCO明显增加(P<0.05)。利拉鲁肽组肺通气功能指标及弥散功能指标均明显高于胰岛素组(P值均<0.05)。结论 2型糖尿病血糖控制不良患者肺功能明显降低,与胰岛素比较,利拉鲁肽可明显改善2型糖尿病患者肺功能。
Forty patients with glycated hemoglobin> 9% type 2 diabetes were randomly divided into insulin group and liraglutide group (n = 20), and 22 cases were used as control. Pulmonary function tests and DLCO ). Results Compared with the control group, the pulmonary function indexes (VC, FVC, FEV1, TLC, MVV) and DLCO of type 2 diabetic patients were significantly decreased (P <0.05). After 12 weeks, the lung function index of insulin group increased slightly, but no statistical significance, while the diffusion function index DLCO increased significantly (P <0.05). Liraglutide group of pulmonary ventilation function indicators and diffuse function indicators were significantly higher than the insulin group (P all <0.05). Conclusions Lung function in patients with type 2 diabetes with poor glycemic control is significantly lower than that with insulin, and liraglutide can significantly improve pulmonary function in patients with type 2 diabetes.